SCHEMBL4074176

SCHEMBL4074176

CCNC(=O)N(Cc1ccc2c(c1)OCO2)Cc1cnc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TSHR P16473 4/20 0.49
MAPK1 P28482 4/20 0.49
GAA P10253 1/20 0.49
PKM P14618 1/20 0.46
USP2 O75604 1/20 0.46
NPC1 O15118 1/20 0.45
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HPGD P15428 3/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 3/20 0.43
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4070774 0.87 PKM (0.52) ALDH1A1SMN1; SMN2NPSR1TSHRMAPK1
SCHEMBL4079906 0.77 FYN (0.61) ALDH1A1NPSR1TSHRMAPK1GAA
SCHEMBL4080216 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPSR1TSHRMAPK1
SCHEMBL4077914 0.73 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2NPSR1TSHRGAA
SCHEMBL29432986 0.71 KDM4E (0.71) NPC1MEN1KMT2AKDM4EPOLB
SCHEMBL4080208 0.69 KDM4E (0.56) ALDH1A1SMN1; SMN2NPSR1TSHRPKM
SCHEMBL4071461 0.69 KDM4E (0.57) ALDH1A1NPSR1TSHRGAAPKM
SCHEMBL11666109 0.67 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2NPSR1TSHRGAA
SCHEMBL30345286 0.66 SRD5A2 (0.54) ALDH1A1SMN1; SMN2NPSR1MAPK1GAA
SCHEMBL13359258 0.66 HPGD (0.64) ALDH1A1SMN1; SMN2MAPK1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG ALDH1A1 1055/4885SMN1; SMN2 4654/4885NPSR1 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.